CBDX Stock Overview
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Curative Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0015 |
| 52 Week High | US$0.0015 |
| 52 Week Low | US$0.0005 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 200.00% |
| 3 Year Change | -99.09% |
| 5 Year Change | -99.62% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CBDX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.5% | -3.2% |
| 1Y | 200.0% | 9.7% | 19.3% |
Return vs Industry: CBDX exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: CBDX exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| CBDX volatility | |
|---|---|
| CBDX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBDX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CBDX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Richard Damion | curativebio.com |
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017.
Curative Biosciences, Inc. Fundamentals Summary
| CBDX fundamental statistics | |
|---|---|
| Market cap | US$57.76k |
| Earnings (TTM) | -US$518.10k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CBDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$518.10k |
| Earnings | -US$518.10k |
Last Reported Earnings
Mar 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CBDX perform over the long term?
See historical performance and comparison